Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Alvotech

Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.

Fuji Pharma

Shinhan Capital

Alvogen

Athos Capital

Aztiq

Aztiq Pharma

Baxter Ventures

Happy International Day of Women and Girls in Science! Women and girls represent half of the world’s population, but remain underrepresented in Science, Technology, Engineering and Mathematics, the STEM fields. Alvotech has achieved and strives to maintain gender balance in its workforce. Diversity increases the pool of talent , brings in fresh perspectives, and creativity. #womeninscience #equality #diversity #STEM

We are so happy to announce that Tanya Zharov, Alvotech’s Chief Legal Counsel, has been awarded the Icelandic Association of Businesswomen’s (FKA) highest honor, in recognition of extraordinary personal achievement and acts of inspiration for other women.

Congratulations also to the recipients of FKA's encouragement and gratitude awards, Inga Tinna Sigurðardóttir, founder of Dineout and Guðlaug Rakel Guðjónsdóttir, Managing Director of Sudurnes Hospital & Health Center. #FKA #WomenInBusiness

We are thrilled to receive European marketing authorization for our ustekinumab biosimilar, which will be marketed by STADA Group in Europe. This is the first ustekinumab biosimilar to be approved by the European Commission. Previously, the biosimilar was also approved in Canada and Japan. We're excited about spearheading biosimilar competition in the ustekinumab market and increasing patient access to biologic therapies! #biosimilars #HealthAccess https://ow.ly/Q50B50QpwCK

Ready for another whirlwind ride around the sun? After this extraordinary year, we can hardly wait! #366days #NewYear #2024

Snow in Reykjavik , the aroma of hot chocolate ☕ and Yule songs 🎅 filling the air. Today's winter solstice heralds longer days. May your holidays be merry and bright.🎄

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	31.92M -	66.62M 108.71%	36.77M 44.80%	83.03M 125.79%	91.43M 10.12%
cost of revenue				64.09M -	160.86M 150.96%
gross profit	31.92M -	66.62M 108.71%	36.77M 44.80%	18.93M 48.51%	-69.42M 466.65%
selling and marketing expenses
general and administrative expenses	48.57M -	58.91M 21.31%	84.13M 42.81%	186.74M 121.96%	76.56M 59.00%
selling general and administrative expenses	48.57M -	58.91M 21.31%	84.13M 42.81%	186.74M 121.96%	76.56M 59.00%
research and development expenses	95.56M -	148.07M 54.96%	191.01M 29.00%	180.62M 5.44%	210.83M 16.72%
other expenses	-50.76M -	-2.83M 94.42%	-2.91M 2.79%	-1.99M 31.73%
cost and expenses	93.37M -	204.15M 118.66%	272.23M 33.35%	429.47M 57.76%	446.29M 3.92%
operating expenses	93.37M -	204.15M 118.66%	272.23M 33.35%	365.38M 34.22%	285.44M 21.88%
interest expense	95.75M -	97.47M 1.79%	117.36M 20.41%	188.42M 60.55%	133.17M 29.32%
ebitda	-48.11M -	-125.67M 161.20%	-168.11M 33.77%	-326.07M 93.96%	-334.64M 2.63%
operating income	-61.45M -	-137.54M 123.83%	-235.46M 71.19%	-346.44M 47.14%	-354.86M 2.43%
depreciation and amortization	13.34M -	11.87M 11.01%	67.35M 467.51%	20.37M 69.76%	24.21M 18.86%
total other income expenses net	-147.94M -	-154.23M 4.26%	86.26M 155.93%	-205.21M 337.90%	-166.19M 19.01%
income before tax	-209.38M -	-291.77M 39.35%	-149.20M 48.86%	-551.65M 269.74%	-651.05M 18.02%
income tax expense	491K -	-121.73M 24,891.45%	-47.69M 60.82%	-38.07M 20.18%	-99.32M 160.90%
net income	-209.88M -	-170.04M 18.98%	-101.50M 40.31%	-513.58M 405.97%	-551.73M 7.43%
weighted average shs out	243.65M -	31.25M 87.17%	31.25M 0%	197.72M 532.71%	227.26M 14.94%
weighted average shs out dil	243.65M -	31.25M 87.17%	31.25M 0%	197.72M 532.71%	227.26M 14.94%
eps	-0.86 -	-5.44 532.56%	-3.25 40.26%	-2.60 20%	-2.43 6.54%
epsdiluted	-0.86 -	-5.44 532.56%	-3.25 40.26%	-2.60 20%	-2.43 6.54%

NASDAQ:ALVOW

Alvotech

Last Close

11.65

30/08 20:00

Market Cap

3.65B

Beta: -

Volume Today

73.83K

Avg: -

PE Ratio

−5.85

PFCF: −11.61

Preview